RVRC.US Revium Recovery Inc
- Market cap
- USD 86.8M
- P/E
- -
- P/B
- -
- ROE
- -0.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is RVRC.US undervalued?
Graham numberThe Graham number of Revium Recovery Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Revium Recovery Inc fundamental analysis
No fundamental analysis for Revium Recovery Inc yet.
Revium Recovery Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Revium Recovery Inc
Revium Rx. operates as a pre-clinical stage biopharmaceutical company focused on the development of nanoparticle-based therapies in the United States. The company develops lipid-based platforms for a variety of uses including antimicrobial resistance and solid tumors; specializes in infectious diseases, including antibiotic-resistant infections, solid tumors, and vaccination; and develops nano-liposomal particles (NLP) based pharmaceutical candidates. It also offers Nano-Mup…
Full company profileRevium Recovery Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Revium Recovery Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2008 | 2009 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Gross Profit | - | - | - | - | - | - | -2.00K | -2.00K | -4.00K | - | - |
| Operating Income | - | - | -4.91K | -24.2K | -551K | -1.79M | -1.13M | -679K | -3.54M | 13.1M | 2.94K |
| EBITDA | - | - | -4.91K | -24.2K | -345K | -1.79M | -1.19M | -678K | -3.47M | -3.46M | 1.06K |
| Net Income | - | - | -4.91K | -24.1K | -558K | -1.80M | -1.21M | -683K | -3.48M | -13.4M | -2.95K |
| EPS | - | - | -0.06 | -0.31 | -1.57 | -0.16 | -0.04 | -0.02 | -0.06 | -0.22 | -0.05 |
| Balance Sheet | |||||||||||
| Total Assets | - | - | 2.50K | - | 1.61M | 1.00M | 460K | 5.63M | 19.2M | 8.30M | 7.11M |
| Total Liabilities | - | - | 7.41K | - | 355K | 64.0K | 70.0K | 144K | 360K | 1.42M | 1.59M |
| Shareholders' Equity | - | - | -4.91K | - | 1.25M | 936K | 390K | 5.49M | 18.8M | 6.88M | 5.52M |
| Cash & Short-term Investments | - | - | - | - | 1.34M | 874K | 426K | 5.48M | 5.28M | 2.71M | 1.51M |
| Total Debt | - | - | 7.41K | - | 163K | 1.00K | 1.00K | 1.00K | 1.00K | 102K | 129K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -5.77M | 3.23M | - | -1.65K | -393K | -939K | -821K | -629K | -1.21M | -2.53M | -2.33M |
| Capital Expenditure | 2.67M | 0.00 | - | 0.00 | 3.00K | 1.00K | 2.00K | 1.00K | 3.00K | 7.00K | 0.00 |
| Free Cash Flow | - | - | - | -1.65K | -396K | -940K | -823K | -630K | -1.21M | -2.54M | -2.33M |
| Ratios | |||||||||||
| ROE | - | - | - | - | -44.5% | -192.3% | -311.0% | -12.4% | -18.5% | -195.5% | -0.1% |
| ROA | - | - | -196.5% | - | -34.7% | -180.0% | -263.7% | -12.1% | -18.2% | -162.1% | 0.0% |
| Debt to Equity | - | - | - | - | 0.13x | 0.00x | 0.00x | 0.00x | 0.00x | 0.01x | 0.02x |
What these items mean
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Revium Recovery Inc dividends
Revium Recovery Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:500 on Dec 9, 2020.
Who owns Revium Recovery Inc
- Insiders 56.70%
- Institutions 0.00%
- Public & others 43.30%
- Shares outstanding 60.7M
- Free float 26.3M
Revium Recovery Inc company profile
- Company name
- Revium Recovery Inc
- Ticker
- RVRC.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Technology
- Employees
- 3
- Fiscal year end
- December
- Address
- Azrieli Business Center, Herzliya, Israel, 4672561
- Phone
- 1 800 519 1687
- Website
- reviumrx.com
About Revium Recovery Inc
Revium Rx. operates as a pre-clinical stage biopharmaceutical company focused on the development of nanoparticle-based therapies in the United States. The company develops lipid-based platforms for a variety of uses including antimicrobial resistance and solid tumors; specializes in infectious diseases, including antibiotic-resistant infections, solid tumors, and vaccination; and develops nano-liposomal particles (NLP) based pharmaceutical candidates. It also offers Nano-Mupirocin, a NLP-based formulation of potent antibiotic mupirocin. In addition, the company develops nanoparticles-based formulation of an angiotensin receptor blockers; novel adjunct for cancer therapies: and novel immunization based on liposomal protein-loaded technology. The company was formerly known as Revium Recovery Inc. and changed its name to Revium Rx. in December 2024. Revium Rx. was incorporated in 1997 and is headquartered in Herzliya, Israel.
Revium Recovery Inc management
2- Mr. Amir Avraham CPAChief Executive Officer · born 1977
- Mr. Igor BluvsteinChief Financial Officer · born 1982